侵袭性垂体瘤治疗方法的研究进展  

Research advances in treatment of aggressive pituitary adenomas

作　　者：刘红艳[1] 谷伟军[1] 母义明[1] LIU Hongyan;GU Weijun;MU Yiming(Department of Endocrinology,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军总医院第一医学中心内分泌科,北京100853

出　　处：《解放军医学院学报》2023年第4期424-428,共5页Academic Journal of Chinese PLA Medical School

基　　金：北京市科委其他项目(Z201100005520014)。

摘　　要：垂体瘤是最常见的颅内肿瘤,大多数属于良性肿瘤。少数肿瘤呈侵袭性生长,其特点为侵袭周围的解剖结构、对常规治疗抵抗、术后早期复发率高。目前,侵袭性垂体瘤的治疗仍然是一个挑战。本文从三个方面综述侵袭性垂体瘤的治疗进展:(1)标准的治疗方案为再手术治疗或放射治疗,能在一定程度降低激素分泌水平,但不能控制肿瘤进展;(2)替莫唑胺被推荐作为侵袭性垂体瘤的一线化疗药物,但只对部分患者有效;(3)肽受体放射性核素治疗、新的分子靶向药物(mTOR抑制剂和表皮生长因子受体抑制剂)和免疫检查点抑制剂已用于治疗侵袭性垂体瘤的临床研究,并且取得了一定的治疗效果,给侵袭性垂体瘤患者带来了希望。Pituitary adenomas,the most common intracranial tumors,are usually benign.However,they may invade the adjacent structures,named invasive pituitary adenomas.Such tumors are characterized by refractory to traditional treatment and higher rate of early recurrence.Up to now,it is still a challenge for clinicians to manage the patients with invasive pituitary adenomas.Standard treatments are repeat surgery or radiotherapy,which can control hypersecretion,but have poor efficacy on tumor progression.Temozolomide is recommended as first-line chemotherapy drug for aggressive pituitary tumors,but it is only effective for partial patients.Peptide receptor radionuclide therapy,novel molecular targeted agents(mTOR inhibitors and EGF inhibitors)and immune-checkpoint inhibitors(ICIs)have been used in clinical researches,bringing hopes to the patients with invasive pituitary adenomas.

关 键 词：侵袭性垂体瘤 治疗 替莫唑胺 分子靶向药物 免疫检查点抑制剂 

分 类 号：R736.4[医药卫生—肿瘤]